Recent Advances of Curcumin Derivatives in Breast Cancer

Yin, Ying; Tan, Yan; Wei, Xueni; Li, Xiaoshun; Chen, Hongfei; Yang, Zehua; Tang, Guotao; Xu, Yongxia; Mi, Pengbin; Zheng, Xing

doi:10.1002/cbdv.202200485

Cited by 10 publications

(12 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results indicated that the inhibitory effect of desired CUR@ZIF-SF-PDA nanoparticles on the proliferation of MCF-7 and SK-BR-3 cells was correlated with DNA damage-induced G2/M phase arrest. This observation is in line with previous reports that CUR and its derivates demonstrated anti-cancer activity by increasing G2/M cell cycle arrest in various breast cancer cell lines, including T47D and MDA-MB-231 cells [94][95][96]. On the other hand, CUR and CUR-loaded nanoparticles treatments showed less effect on the cell cycle distribution of AD-293 human embryonic kidney cells (Figure 8f) compared with MCF-7 and SK-BR-3 breast cancer cells (Figure 8d,e), suggesting that desired nanoparticles induced less DNA damage on non-cancer cells than that on breast cancer cells in line with the MTT data above.…”

Section: Cell Cycle Analysissupporting

confidence: 92%

Microfluidic-Assisted ZIF-Silk-Polydopamine Nanoparticles as Promising Drug Carriers for Breast Cancer Therapy

Gao,

Mansor,

Winder

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Metal–organic frameworks (MOFs) are heralded as potential nanoplatforms for biomedical applications. Zeolitic imidazolate framework-8 (ZIF-8), as one of the most well known MOFs, has been widely applied as a drug delivery carrier for cancer therapy. However, the application of ZIF-8 nanoparticles as a therapeutic agent has been hindered by the challenge of how to control the release behaviour of anti-cancer zinc ions to cancer cells. In this paper, we designed microfluidic-assisted core-shell ZIF-8 nanoparticles modified with silk fibroin (SF) and polydopamine (PDA) for sustained release of zinc ions and curcumin (CUR) and tested these in vitro in various human breast cancer cells. We report that microfluidic rapid mixing is an efficient method to precisely control the proportion of ZIF-8, SF, PDA, and CUR in the nanoparticles by simply adjusting total flow rates (from 1 to 50 mL/min) and flow rate ratios. Owing to sufficient and rapid mixing during microfluidic-assisted nanoprecipitation, our designer CUR@ZIF-SF-PDA nanoparticles had a desired particle size of 170 nm with a narrow size distribution (PDI: 0.08), which is much smaller than nanoparticles produced using traditional magnetic stirrer mixing method (over 1000 nm). Moreover, a properly coated SF layer successfully enhanced the capability of ZIF-8 as a reservoir of zinc ions. Meanwhile, the self-etching reaction between ZIF-8 and PDA naturally induced a pH-responsive release of zinc ions and CUR to a therapeutic level in the MDA-MB-231, SK-BR-3, and MCF-7 breast cancer cell lines, resulting in a high cellular uptake efficiency, cytotoxicity, and cell cycle arrest. More importantly, the high biocompatibility of designed CUR@ZIF-SF-PDA nanoparticles remained low in cytotoxicity on AD-293 non-cancer cells. We demonstrate the potential of prepared CUR@ZIF-SF-PDA nanoparticles as promising carriers for the controlled release of CUR and zinc ions in breast cancer therapy.

show abstract

Section: Cell Cycle Analysissupporting

confidence: 92%

Microfluidic-Assisted ZIF-Silk-Polydopamine Nanoparticles as Promising Drug Carriers for Breast Cancer Therapy

Gao,

Mansor,

Winder

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…218 Many studies on different cancer treatments (both preclinical and clinical trials) have shown that CUR is a promising anticancer agent that can be used alone or in combination with other drugs. [219][220][221][222][223][224] However, CUR's clinical application in BC is constrained by its low bioavailability, poor water solubility, short halflife, fast metabolism, and inadequate tumor targeting capacity. Therefore, researchers have developed different drug delivery systems to address these problems, and great progress has been made in recent years.…”

Section: Discussionmentioning

confidence: 99%

Targeted Drug Delivery Systems for Curcumin in Breast Cancer Therapy

Huang¹,

Zhai²,

Fan³

et al. 2023

IJN

View full text Add to dashboard Cite

Breast cancer (BC) is the most prevalent type of cancer in the world and the main reason women die from cancer. Due to the significant side effects of conventional treatments such as chemotherapy and radiotherapy, the search for supplemental and alternative natural drugs with lower toxicity and side effects is of interest to researchers. Curcumin (CUR) is a natural polyphenol extracted from turmeric. Numerous studies have demonstrated that CUR is an effective anticancer drug that works by modifying different intracellular signaling pathways. CUR's therapeutic utility is severely constrained by its short half-life in vivo, low water solubility, poor stability, quick metabolism, low oral bioavailability, and potential for gastrointestinal discomfort with high oral doses. One of the most practical solutions to the aforementioned issues is the development of targeted drug delivery systems (TDDSs) based on nanomaterials. To improve drug targeting and efficacy and to serve as a reference for the development and use of CUR TDDSs in the clinical setting, this review describes the physicochemical properties and bioavailability of CUR and its mechanism of action on BC, with emphasis on recent studies on TDDSs for BC in combination with CUR, including passive TDDSs, active TDDSs and physicochemical TDDSs.

show abstract

“…Curcumin is mainly used for treating cancer. ( Rajendran et al, 2022 ; Tang et al, 2022 ; Vadukoot et al, 2022 ; Wang et al, 2022 ; Yin et al, 2022 ). However, the anticancer activity of curcumin has not been fully elucidated in vivo and in vitro .…”

Section: Introductionmentioning

confidence: 99%

Interactions between curcumin and human salt-induced kinase 3 elucidated from computational tools and experimental methods

et al. 2023

View full text Add to dashboard Cite

Natural products are widely used for treating mitochondrial dysfunction-related diseases and cancers. Curcumin, a well-known natural product, can be potentially used to treat cancer. Human salt-induced kinase 3 (SIK3) is one of the target proteins for curcumin. However, the interactions between curcumin and human SIK3 have not yet been investigated in detail. In this study, we studied the binding models for the interactions between curcumin and human SIK3 using computational tools such as homology modeling, molecular docking, molecular dynamics simulations, and binding free energy calculations. The open activity loop conformation of SIK3 with the ketoenol form of curcumin was the optimal binding model. The I72, V80, A93, Y144, A145, and L195 residues played a key role for curcumin binding with human SIK3. The interactions between curcumin and human SIK3 were also investigated using the kinase assay. Moreover, curcumin exhibited an IC50 (half-maximal inhibitory concentration) value of 131 nM, and it showed significant antiproliferative activities of 9.62 ± 0.33 µM and 72.37 ± 0.37 µM against the MCF-7 and MDA-MB-23 cell lines, respectively. This study provides detailed information on the binding of curcumin with human SIK3 and may facilitate the design of novel salt-inducible kinases inhibitors.

show abstract

Recent Advances of Curcumin Derivatives in Breast Cancer

Cited by 10 publications

References 96 publications

Microfluidic-Assisted ZIF-Silk-Polydopamine Nanoparticles as Promising Drug Carriers for Breast Cancer Therapy

Microfluidic-Assisted ZIF-Silk-Polydopamine Nanoparticles as Promising Drug Carriers for Breast Cancer Therapy

Targeted Drug Delivery Systems for Curcumin in Breast Cancer Therapy

Interactions between curcumin and human salt-induced kinase 3 elucidated from computational tools and experimental methods

Contact Info

Product

Resources

About